Lifevantage Corp Stock Price, News & Analysis

LifeVantage (Nasdaq: LFVN), a leader in health and wellness, announced its participation in the Water Tower Fireside Chat Series on December 3, 2024. The event will feature presentations by Steve Fife, President and CEO, and Carl Aure, CFO, scheduled for 11:00 a.m. Eastern Time. The presentation will be webcasted and accessible via the company's Investor Relations website at https://lifevantage.gcs-web.com/.

LifeVantage (Nasdaq: LFVN) has reintroduced its TrueScience® TruePout Hydrating Lip Oil to the US market for Cyber Monday. The product is being sold as a three-pack with French Vanilla flavor and features plant-based ingredients. The lip oil offers hydration through plant-based squalane, exfoliation via pineapple extract, and nourishment from seed oils and fruit extracts. Available pricing tiers include Consultant Price at $75.99, Subscription Price at $85.49, and Retail Price at $94.99. The product is available exclusively through US Consultants and the LifeVantage website while supplies last.

LifeVantage (Nasdaq: LFVN), a health and wellness company focusing on cellular-level health products, has announced its participation in the upcoming Sidoti Micro Cap Conference. Steve Fife, President and CEO, and Carl Aure, CFO, will conduct virtual investor meetings and deliver a presentation on November 13, 2024, at 1:00 p.m. Eastern Time. The presentation will be available via live webcast through the company's Investor Relations website.

LifeVantage reported Q1 fiscal 2025 results with revenue of $47.2 million, down 8.1% year-over-year. Net income per diluted share increased to $0.14 from $0.05 in the prior year. The company launched the MindBody GLP-1 System™ on October 11th. Revenue declined 4.2% in Americas and 19.7% in Asia/Pacific & Europe. Despite lower revenues, adjusted EBITDA improved 11% to $4.4 million. The company maintains its fiscal 2025 guidance of $200-210 million in revenue and adjusted earnings per share of $0.70-$0.80.

LifeVantage (Nasdaq:LFVN) has announced that its Board of Directors has approved a quarterly cash dividend of $0.04 per share of common stock. The dividend will be paid on December 16, 2024 to stockholders of record at the close of business on December 2, 2024. LifeVantage is a health and wellness company focusing on products that activate optimal health processes at the cellular level.

LifeVantage (LFVN) announced results from a human clinical trial of their MindBody GLP-1 System™, showing a 140% average increase in GLP-1 levels and significant weight loss outcomes. The 12-week study involved 60 subjects with BMI≥25, divided into three groups. Key findings include: 92% of participants lost weight (average 11 pounds), 92% reduced total body fat, and 71% decreased visceral fat. Notably, participants reported improved relationships with food, with 95% experiencing decreased sugar cravings and 96% reducing portion sizes. The system uses natural ingredients to activate GLP-1 production without reported side effects.

LifeVantage (Nasdaq: LFVN), a health and wellness company focusing on cellular-level health products, has announced its participation in the LD Micro Main Event XVII. The event will take place from October 28-30, 2024, in Los Angeles, CA. Steve Fife, President and CEO, and Carl Aure, CFO, will conduct investor meetings and deliver a presentation on October 30, 2024, at approximately 4:30 p.m. Eastern Time. The presentation will be available via live webcast on the company's Investor Relations website.

LifeVantage (Nasdaq:LFVN), a health and wellness company focusing on cellular health, has announced it will release its first quarter fiscal year 2025 financial results on October 29, 2024, after the stock market closes. The company will host a conference call for investors at 2:30 p.m. Mountain Time (4:30 p.m. Eastern Time) on the same day.

Investors can participate in the live call by dialing (877) 704-4453 from the U.S. or (201) 389-0920 for international callers. A telephone replay will be available until November 12, 2024. Additionally, a live webcast will be accessible on the company's Investor Relations website, with an archive available for approximately 30 days.

LifeVantage (Nasdaq: LFVN) has launched its patent-pending MindBody GLP-1 System™ in the U.S., a dual-product solution designed to balance hunger hormones and support sustainable weight management. The system includes MB Core™ and MB Enhance™, which together increase natural GLP-1 production by an average of 140%.

Clinical trials showed that the system helped participants lose up to 27% of visceral fat and 5% of total body fat while maintaining muscle. The product launch at Market Connect in Kansas City met with high demand, with on-site products selling out quickly and e-commerce sales exceeding forecasts.

The MindBody GLP-1 System™ works by increasing GLP-1 production, activating GLP-1 receptor sites, and reducing the activity of enzymes that break down GLP-1. This approach aims to provide a comprehensive solution for long-term weight management and overall wellness.